Loading clinical trials...

Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis | Clinical Trials | Clareo Health

RECRUITINGNA

Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis

NCT06307080•Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

View on ClinicalTrials.gov

Summary

1. Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy. 3. Transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. age 18-70 years old, gender is not limited;
•2. Newly diagnosed pancreatic cancer with liver metastasis confirmed by pathology or consistent with clinical diagnosis, and no metastases to organs other than the liver;
•3. Imaging evaluable tumors with safe access to puncture;
•4. The number of half liver tumors ≤3 and the size of each tumor ≤3 cm;
•5. ECOG PS score ≤2 points, expected survival \> 3 months.

Exclusion Criteria

•1. Liver function Child-Pugh grade C, severe jaundice, especially obstructive jaundice;
•2. The liver is significantly atrophy, the tumor is too large, and the ablation range needs to reach one-third of the liver volume;
•3. Expected survival \< 3 months;
•4. serious heart, lung, liver and kidney dysfunction and coagulation dysfunction;
•5. Uncontrolled co-morbidities, including poorly controlled hypertension or diabetes, persistent active infections, or mental illness or social conditions that may affect participants' compliance with the study;
•6. refractory ascites, pleural fluid or bad fluid;
•7. Pregnancy or breastfeeding;
•8. The researcher considers that there are any other factors that are not suitable for inclusion or affect the participant's participation in the study.

Locations (1)

Shanghai General Hospital

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

October 8, 2023

Primary Completion Date

December 31, 2025

Completion Date

December 31, 2026

Last Updated

July 9, 2025

Enrollment

ESTIMATED participants

Conditions

Pancreatic Cancer

Interventions

Multi-mode thermal ablation device

DEVICE

Intravenous anti-PD-1 and chemotherapy

DRUG

Contacts

Long Jiang, MD

CONTACT

18017317460 jiang.long@shgh.cn

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE1/PHASE2

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 9, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Resilience and Equity in Aging, Cancer, and Health (REACH)

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients